<DOC>
	<DOCNO>NCT01262716</DOCNO>
	<brief_summary>This study ass safety ergonomics/engineering design novel cancer treatment , Continuous Low Irradiance Photodynamic therapy ( CLIPT ) . We assess effect primary metastatic tumor involve skin , particular improve functionality , efficiency wearability light delivery device ( LDD ) well overall treatment subject chest wall recurrence breast cancer . An ongoing study ( IRB # 8227 ) , sponsor Susan G. Komen Breast Cancer Foundation grant , use 1st generation LDD device evaluate determined dose-limiting toxicity CLIPT subject chest wall recurrence breast cancer . A Diomed laser device use study . The Diomed laser deliver 630 nm ( red spectrum ) light Fiber Optic Patch . The Fiber Optic patch compatible laser , deliver light designate region patient 's skin .</brief_summary>
	<brief_title>A Novel Therapy Treatment Chest Wall Progression Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Patients &gt; 18 year age , primary metastatic cutaneous tumor may may previously irradiate . ECOG performance status &lt; 3 . Patients must receive systemic anticancer therapy within 30 day prior enrol study . Patients must receive radiation therapy target site within 60 day enrol study . Skin target site control site must grade 0 1 Common Terminology Patients must target lesion normal periumbilical skin cover fiberoptic mesh use deliver CLIPT ( 10 x 10 cm , 3 x 3 ) . If locate extremity , target lesion must cover 50 % diameter extremity level locate . Absolute neutrophil count &gt; 1000 . Adequate coagulation status indicate platelet count &gt; 50,000 , PT PTT &lt; 1.5 time upper limit normal . Patients must sign informed consent . Male patient consider study . Patients must target lesion location hand , foot , genitals , face . Lesions location exclude . Patients medical condition associate photosensitivity , cutaneous porphyria collagen vascular disease , know allergy porphyrin exclude . Pregnant nursing patient exclude . Women childbearing potential must negative serum urine pregnancy test prior enrollment . Patients take medication know cause photosensitivity ( tetracycline , sulfonamide , phenothiazine , sulfonylurea hypoglycemic agent , thiazide diuretic , griseofulvin , fluoroquinolones , St. John 's wort amiodarone ) exclude . Patients severe hepatic dysfunction ( total bilirubin , AST , ALT &gt; five time upper limit normal ) exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Chest wall progression breast cancer</keyword>
	<keyword>PDT</keyword>
	<keyword>Photofrin</keyword>
	<keyword>Photosensitizer</keyword>
</DOC>